PubMed Health⌕ Search

SEARCH · PubMed Health

Results for “Vaccine Development”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 1,297 records · Page 72Linked to original sources

Incidence and prognosis of meningitis due to Haemophilus influenzae, Streptococcus pneumoniae and Neisseria meningitidis in Sweden.

The incidence, concomitant conditions and case fatality rate of Haemophilus influenzae (Hi) and pneumococcal meningitis and of invasive meningococcal infections were studied retrospectively in Sweden (population 8.4 million) for the years 1987-89, the period before vaccination against Hi type b started. A total of 1,019 cases with culture-verified infection were found. The incidence rates per 100,000 per year were 1.8 for Hi meningitis, 1.2 for pneumococcal meningitis and 1.0 for invasive meningococcal infections. The age-specific incidence was highest in the 3-23 months age group for the 3 bacterial species. Pneumococcal meningitis was common in individuals > or = 60 years and meningococcal infections in the age-group 10-24 years. A serious concomitant condition was known in 57% of all patients with pneumococcal meningitis while this was uncommon for the other organisms. The case fatality rate was 2% for Hi meningitis, 24% for pneumococcal meningitis and 10% for meningococcal infections. All 81 pneumococcal isolates which had been serotyped belonged to serotypes in the 23-valent pneumococcal vaccine. Of the meningococcal isolates, 65% belonged to serogroup B. In conclusion, the high incidence of Hib meningitis justifies general Hib vaccination. Development of a vaccine against N. meningitidis group B should have high priority. Furthermore, improved pneumococcal vaccines are needed for patients with predisposing conditions. The currently available pneumococcal polysaccharide vaccine seems to be underused.

Adolescent↗

Prevention strategies for respiratory syncytial virus: passive and active immunization.

Prevention of respiratory syncytial virus (RSV) disease may ultimately be possible with active immunization, although no vaccine is currently available. Formalin-inactivated RSV vaccine caused serious disease in some recipients re-exposed to RSV, which slowed vaccine development. Current RSV vaccine candidates include RSV fusion protein vaccines, chimeric fusion protein-glycoprotein vaccines, and various live, attenuated RSV vaccines. RSV vaccines may be problematic in very young infants and newborns because of the relatively poor immunogenicity of most vaccine candidates to date. Passive immunization with human polyclonal intravenous immune globulin and humanized monoclonal antibody directed against the conserved fusion protein of RSV prevents severe RSV disease, although not necessarily viral infection. The humanized RSV monoclonal antibody is licensed for use in premature infants and infants with bronchopulmonary dysplasia and is being evaluated in infants with cardiac disease. Another innovative approach to prevent RSV disease in young infants is maternal immunization with a vaccine such as the purified fusion protein vaccine. Such a vaccine could stimulate antibody response to RSV surface glycoproteins and potentially prevent RSV disease in the mother, while maternal antibodies produced could be passively transmitted across the placenta to the infant. A pilot study in postpartum women demonstrated immunogenicity with no significant adverse reactions.

Antibodies, Monoclonal↗

Recent advances in improved tuberculosis vaccines.

Tuberculosis continues to be a major infectious cause of global morbidity and mortality, both in children and adults, in spite of widespread vaccination of infants with Bacille Calmette-Guerin (BCG) and the availability of effective antibiotics. The failure of BCG to significantly affect disease incidence in adults in many endemic countries, combined with the growing HIV epidemic and the appearance of multidrug resistant strains of Mycobacterium tuberculosis, threatens to overwhelm current tuberculosis control strategies. This unfortunate state of affairs has driven an intensive search for better tuberculosis vaccines. This article reviews the various vaccine development strategies which are being used e.g., purification or synthesis of protein peptide and non-peptide antigens from M. tuberculosis, creation of rationally-attenuated mutants of BCG and M. tuberculosis, development of DNA vaccines based upon the published genome sequence, the cloning of mycobacterial genes into living vaccine carrier strains (e.g., attenuated Salmonella, vaccinia virus, etc), or the use of naturally attenuated mycobacterial species (e.g., M. vaccae, M. microti). The animal models in which these vaccine candidates are being screened for protective efficacy (e.g., the mouse, guinea pig, rabbit, primate) will be discussed briefly. Finally, some of the challenges inherent in the eventual clinical evaluation of new tuberculosis vaccines are reviewed.

Adult↗

[DNA vaccines for veterinary medicine].

DNA vaccination represents one of the most recent novel approaches to vaccine development. Experimentally, DNA vaccines induce a broad range of long lasting immune responses including humoral and cell-mediated immunity against infectious diseases in humans and animals. Furthermore, DNA vaccines are potentially useful for the treatment of autoimmune diseases or cancer. However, most information on the efficacy of DNA vaccines has been generated in mice and studies in larger animals are limited. In this review, the potential application of DNA vaccines in livestock and pet animals are discussed. The principle of this new technology, its potency and future perspectives for use in veterinary medicine will be outlined.

Animal Diseases↗

[The recombinant vaccinia viruses expressing HPV type 16 wild or mutant E7 protein elicit immunity against tumor cells in mice].

OBJECTIVE: To select mutants of HPV 16 E7 suitable for vaccine development. METHODS: Several recombinant vaccinia viruses (VwE7, VmE7-1, and VmE7-2) expressing wild E7 or its mutants, ME7-1 (24G26G) and ME7-2 (24G26G91G) respectively, were employed to study their antigenicity and anti tumor activity. RESULTS: Both VmE7-1 and VwE7 could elicit cytotoxic T lymphocytes (CTL)and protect mice against tumor cells challenge, but VmE7-2 could not induce the immune reactions compared with VmE7-1 and VwE7. CONCLUSIONS: It suggested that ME7-1 could be used to develop a therapeutic vaccine for cervical cancer.

Animals↗

Molecular targets for immunocontraception.

Effective contraception is necessary in countries where limiting population growth has become a public policy imperative. The main antigenic targets for contraceptive vaccine development can be listed as following: 1) sperm antigens, 2) zona pellucida antigens, 3) gonadotrophin-releasing hormone, 4) chorionic gonadotrophin, 5) other protein/peptide hormones (follicle-stimulating hormone, luteinizing hormone, luteinizing hormone-releasing hormone), and 6) gonadal steroid hormones. New techniques, such as the application of monoclonal antibodies, hybridoma and DNA recombinant technologies, have become useful in search for contraceptive candidates. Current state of development of contraceptive vaccines based on specific antigenic targets and trials in animal/human models are presented in this article.

Animals↗

Production of formalinized poliomyelitis vaccine (Salk-type) on a semi-industrial scale.

This article describes a semi-industrial method for the production of formalinized poliomyelitis vaccine developed during 1956. The general technique followed that originally devised by Salk with modifications developed locally. The vaccine was tested for safety and innocuity according to the Minimum Requirements laid down by the United States Public Health Service. Seitz filtration was found to be essential for the production of a non-infectious vaccine; filtration through glass filters proved to give inconsistent results. High initial virus titres, proper filtration methods, and the use of a sensitive tissue-culture system for safety testing were considered to be of prime importance for the production of a safe and effective vaccine. Over 60 000 infants and young children were inoculated with this vaccine in a country-wide immunization programme during the winter and spring of 1957. No untoward effects were noted; an immunological evaluation of its performance in those inoculated is in progress.

Child↗

Stimulation of human T cells by an influenza A vector expressing a CTL epitope from the HER-2/neu protooncogene results in higher numbers of antigen-specific TCRhi cells than stimulation with peptide. Divergent roles of IL-2 and IL-15.

Development of cancer vaccines requires approaches to induce expansion and functional differentiation of tumor antigen-specific effector and memory cells. The later are particularly relevant for prevention of disease relapse. Efficient induction of memory cells is hindered by the lack of information about the relationship between TCR stimulation and the cytokines required for Ag-specific memory CD8+ cells and proliferation and survival. Since viruses are known to induce memory T cells, an attenuated influenza A/PR8/34 virus with a truncated nonstructural (NS1) gene was generated containing the HER-2 CTL E75 epitope in its neuraminidase protein (KIF-NS virus). Stimulation of PBMC from healthy donors and of tumor-associated lymphocytes (TAL) from ovarian cancer patients with dendritic cells (DC) infected with KIF-NS (KIF-NS-DC), induced higher numbers of immediate memory effector CD8+ CD44hi CD122hi cells, expressing TCR specific for E75 (E75-TCR) than stimulation with peptide E75. Survival of CD44hi CD122hi cells was dependent on the levels of TCR; cells expressing lower levels of E75-TCR (MFI: 10(2)-10(3)) survived better in IL-2 while cells expressing high levels of TCR (MFI: 10(3)-10(4)) survived better in IL-15. This is the first report demonstrating induction of human Ag-specific memory CD8+ cells against a human tumor-antigen using a live attenuated recombinant influenza virus vector. Such vectors may provide a novel approach for preventive immunity in human cancer vaccine development.

Dendritic Cells↗

HIV vaccine knowledge and beliefs among communities at elevated risk: conspiracies, questions and confusion.

HIV vaccines offer the best long-term hope of controlling the AIDS pandemic. We explored HIV vaccine knowledge and beliefs among communities at elevated risk for HIV/AIDS. Participants (N=99; median age=33 years; 48% female; 22% African-American; 44% Latino; 28% white; 6% other) were recruited from seven high-risk venues in Los Angeles, California, using purposive, venue-based sampling. Results from nine focus groups revealed: 1) mixed beliefs and conspiracy theories about the existence of HIV vaccines; 2) hopefulness and doubts about future HIV vaccine availability; 3) lack of information about HIV vaccines; and 4) confusion about vaccines and how they work. Tailored HIV vaccine education that addresses the current status of HIV vaccine development and key vaccine concepts is warranted among communities at risk. Ongoing dialogue among researchers, public health practitioners and communities at risk may provide a vital opportunity to dispel misinformation and rumors and to cultivate trust, which may facilitate HIV vaccine trial participation and uptake of future HIV vaccines.

AIDS Vaccines↗

Using scid mice to study parasitic diseases.

The interaction between parasites and their animal or human hosts is one of the most interesting and important biologic phenomena. Understanding the host-parasite interplay is essential to understanding the pathogenesis of parasitic diseases and for the development of new vaccines and chemotherapy. One approach to identifying key components of the host immune response to parasites is using immunodeficient host models. Scid mice are one of the most useful models of an immunodeficient host. Herein, we describe the use of scid mice to identify the steps in granuloma formation to parasite eggs, devise a screening model for vaccine development, and provide clues to the pathogenesis of opportunistic infections associated with AIDS.

Animals↗

Global biological sample collections from tuberculosis studies: a scoping review.

Progress in tuberculosis vaccine development is hindered by the incomplete understanding of protective immunity and other disease mechanisms. An interconnected network of sample biorepositories from tuberculosis studies could help to address these gaps. To assess the feasibility of such a resource, we conducted a scoping review of tuberculosis observational studies and vaccine clinical trials. The included studies collected at least one biological sample from tuberculosis cases, contacts, or controls and had more than 100 participants. We contacted the corresponding authors of these studies to determine the sample availability and interest in interconnected biorepositories. For the period 2014-24, we identified 104 observational studies and 18 vaccine trials that collected biological samples from 35 075 tuberculosis cases, 39 450 contacts or controls, and 45 628 trial participants across 43 countries. The commonly collected samples were blood, human genomic DNA, RNA, and sputum. Interest among the contacted investigators was high. Interconnected sample biorepositories could facilitate large-scale investigations and accelerate progress towards tuberculosis vaccine development.

Humans↗

Reverse vaccinology.

Biochemical, serological and microbiological methods have been used to dissect pathogens and identify the components useful for vaccine development. Although successful in many cases, this approach is time-consuming and fails when the pathogens cannot be cultivated in vitro, or when the most abundant antigens are variable in sequence. Now genomic approaches allow prediction of all antigens, independent of their abundance and immunogenicity during infection, without the need to grow the pathogen in vitro. This allows vaccine development using non-conventional antigens and exploiting non-conventional arms of the immune system. Many vaccines impossible to develop so far will become a reality. Since the process of vaccine discovery starts in silico using the genetic information rather than the pathogen itself, this novel process can be named reverse vaccinology.

BCG Vaccine↗

Vaccine against human hepatitis B virus prepared from antigen derived from human hepatoma cells in culture.

Vaccine against human hepatitis B was prepared using antigen derived from hepatitis B carrier hepatoma cells grown in the interstices of a Diaflo hollow filter unit. Hepatitis B surface antigen (HBsAg) produced by these cells was purified by immune affinity chromatography, digestion with DNase and pepsin, and Sephadex G-150 separation. The Formalin-treated antigen was formulated in 20-micrograms dose on alum adjuvant with thimerosal added as a preservative. This cell culture vaccine was as potent as human plasma-derived vaccine as measured in a mouse potency assay. The vaccine proved safe in tests in chimpanzees and in human subjects who were in late stages of cancer of the central nervous system and who were receiving therapy for their condition. None of five subjects who received the vaccine developed untoward clinical reactions. Two of the subjects who received all three doses of vaccine developed antibody against HBsAg. Three persons, two given only the primary doses and one who was given all three doses but was lost to follow-up, demonstrated no response. The slow and relatively low antibody responses to the vaccine were similar to those in other immunosuppressed persons who were given vaccine of human plasma origin.

Animals↗

Introducing new vaccines in developing countries: concepts and approaches to estimating burden of Haemophilus influenzae type b-associated disease.

In the past 30 years, great strides have been made in immunizing infants and children routinely in developing countries under the Expanded Programme on Immunization. Despite this, the introduction of Haemophilus influenzae type b (Hib) vaccines has progressed rather slowly compared to previously-introduced vaccines for infant immunizations. This slower uptake has been attributed partly to the need for data on the burden of invasive Hib disease. To understand this need, conceptual underpinnings and prerequisites were explored for Hib disease-burden studies. Methodological approaches were also reviewed for conducting Hib disease-burden studies that may be considered in developing countries. Potential studies span a range of designs that provide varying levels of clinical, laboratory and epidemiologic evidence of the burden of invasive Hib disease. Carefully-conducted studies can lay the foundation for complementary studies of long-term disability due to invasive Hib disease, national economic analysis, and field evaluations of vaccine. Studies done in collaboration with national agencies and clinical investigators will maximize study value and provide critical data for national decision-makers who make choices regarding the introduction of Hib vaccines.

Child, Preschool↗

Perceptions of Shigella and of Shigella vaccine among rural Chinese: compatibility with Western models of behavioral change.

Shigella remain a major source of morbidity and mortality in developing countries, including China. In response, national and international researchers are actively working to develop vaccines that will be effective against dysentery and diarrhea caused by shigella dysentariae. With the growing recognition of the problems associated with sustained vaccine acceptance and usage, researchers and policy makers recognize the importance of conducting theory-based qualitative research to inform vaccine development program efforts. Accordingly we undertook this qualitative study involving 81 residents of one of China's rural communities with high rates of dysentery. The semi-structured interviews suggest that a Western model of behavioral change offered a useful research construct. Consistent with the model is the community's strong perception of 'response efficacy' of vaccines, particularly in comparison with water and sanitation and disease treatment. Residents were eager to vaccinate their children despite variable perception of disease severity, while they were less consistent in their interest in vaccinating adults; this enthusiasm for vaccinating children was attributed to China's 'one child per couple' policy. Intervention implications are discussed.

Attitude to Health↗

High and low responsiveness to vaccines in farm animals.

Low responsiveness in some farm animals is emerging as a problem in the application of newly developed vaccines which operate at skin surfaces and mucous membranes. Breeding for resistance to specific diseases seems to be associated with breeding for specific immune responsiveness in farm animals and very likely this involves selection for major histocompatibility complex (MHC) haplotype. However, other factors contribute to low responsiveness and these include poor nutrition, sire effects, antigenic competition and inadequate effector mechanisms. The future of newly developed vaccines will rest on the solution to the low responder problem, and once solved, the application of these vaccines will be fully utilized for disease control in farm animals.

Animals↗